Kidzpartners Formulary

Total Page:16

File Type:pdf, Size:1020Kb

Kidzpartners Formulary Health Partners Plans CHIP Formulary Updated 01/01/2021 2021 Formulary Introduction be notified through correspondence from Prescription quantities cannot be altered unless the Health Partners Plans Pharmacy approved by the physician, and must be within department when applicable. the limits of the plan’s days’ supply. Health Partners Plans, Inc. is pleased to provide the 2021 KidzPartners Formulary. This Prescribed medications or regimens that are formulary covers members under the Product Selection Criteria non-formulary require prior authorization. KidzPartners (Children’s Health Insurance Program) plan. The drugs listed in the The Health Partners Plans P&T Committee will KidzPartners Formulary are intended to provide consider all FDA approved drugs for inclusion Immediate Need sufficient options to treat the majority of in the formulary. The evaluation process (5/15-day Emergency Supply) patients who require drug therapy in an includes a literature review, and expert opinion ambulatory setting. Excluded from coverage by respected medical professionals. Formal If a member presents at a pharmacy with a are drugs from specific manufacturers who reviews are prepared which typically address prescription which requires prior authorization, have not contracted with the rebate program of the following information: whether for a non-formulary drug or otherwise, the Federal government. 1. Safety and if the prior authorization cannot be 2. Effectiveness processed immediately, Health Partners Plans The drugs listed in the KidzPartners Formulary will allow the pharmacy to dispense an interim have been reviewed and approved by the 3. Comparison studies 4. Approved indications supply of the prescription under the following Health Partners Plans Pharmacy and circumstances: Therapeutics Committee. These drug products 5. Adverse effects have been selected to provide the most 6. Contraindications If the recipient is in immediate need of the clinically appropriate and cost-effective 7. Pharmacokinetics medication in the professional judgment of the medications for KidzPartners members. There 8. Patient compliance considerations pharmacist and if the prescription is for a new may be occasions when an unlisted drug is 9. Medical outcome and medication (one that the recipient has not taken desired for medical management of a specific pharmacoeconomic studies before or that is taken for an acute condition), patient. In those instances, the unlisted Health Partners Plans will allow the pharmacy medication may be requested through Prior When a new drug is considered for formulary to dispense a 5-day supply of the medication to Authorization/ Medical Exception. inclusion, an attempt will be made to examine afford the recipient or pharmacy the opportunity the drug relative to similar drugs currently on to initiate the request for prior authorization. formulary. In addition, entire therapeutic Preface classes are periodically reviewed. This review If the prescription is for an ongoing medication process may result in deletion of a drug(s) in a (one that is continuously prescribed for the The KidzPartners Formulary is organized by particular therapeutic class in an effort to treatment of an illness or condition that is sections, which refer to either a drug/ continually promote the most clinically useful chronic in nature in which there has not been a pharmacologic class or disease state. Each and cost-effective agents. break in treatment for greater than 30 Days), section contains a list of drugs selected to be Health Partners Plans will allow the pharmacy on this formulary. Prescribing a drug product Plan Limits to dispense a 15-day supply of the medication that is available generically is encouraged automatically, unless Health Partners Plans when appropriate. Unless exceptions are mailed to the member, with a copy to the noted, all applicable dosage forms and A maximum of up to a 30-day supply of prescriber, an advance written notice of the strengths of the referenced product generally medication is eligible for coverage. The reduction or termination of the medication at are covered. prescriber is urged to prescribe in amounts that least 10 days prior to the end of the period for adhere to accepted standards of care. The which the medication was previously days’ supply must be accurately determined by authorized. Pharmacy and Therapeutics the dispensing pharmacist to assure (P&T) Committee compliance with plan parameters. Health Partners Plans will respond to the Specific limits based on FDA guidelines, request for prior authorization within 24 hours The actions of the Health Partners Plans medication package inserts and accepted from when the request was received. If the P&T Committee are communicated through standards of care may apply to medication prior authorization is denied, the member is the Provider Newsletter to all physicians treatments under clinical review. entitled to appeal the decision through several and posted on our website. Pharmacy avenues. The 5-day or 15-day requirement providers in the KidzPartners network will does not apply when the pharmacist Health Partners Plans CHIP Formulary Updated 01/01/2021 determines that taking the medication, either When the above two criteria are met, a generic • Medications used for non-FDA approved alone or along with other medication that the can be substituted with the full expectation that indications recipient may be taking, would jeopardize the the substituted product will produce the same • Prescription costs that exceed $1,000 health and safety of the recipient. clinical effect and safety profile as the brand per claim name product. • Prescriptions that exceed set plan limits Formulary Product (days’ supply, quantity, cost) State laws or regulation may indicate the ability Descriptions • Prescriptions processed by non-network to practice generic substitution for selected pharmacies products or categories of drugs. This formulary lists all specific strengths and • New-to-market products • High-end oral and self-administered dosage forms that are covered. When a There are now many brand name products that strength or dosage form is specified, only injectable medications are repackaged or distributed under a generic • Medications with Health Partners Plans the product identified will be covered. Other label. These generic versions should always be strengths/ dosage forms of the referenced P&T Committee approved treatment considered therapeutically equivalent and guidelines product are not covered. substitutable for the source branded product irrespective of rating. To request a prior authorization the For specific questions please contact the physician or a member of his/her staff Health Partners Plans Pharmacy department at Drugs Efficacy Study should contact Health Partners Plans either 215-991-4300. by fax at 866-240-3712, or phone at 215-991- Implementation (DESI) Drugs 4300. All non-emergency requests can be Generic Substitution faxed 24 hours per day; calls should be Health Partners Plans does not reimburse for placed from 9:00 A.M. to 6:00 P.M., Monday DESI drugs. DESI drugs are those drugs first Generic substitution is the process by which a through Friday. marketed between 1938 and 1962 which were generic equivalent is dispensed rather than the approved as safe, but not required to show brand name product. The appropriate use of In the event of an immediate need after effectiveness for FDA product approval. The generic drugs is one method of providing cost business hours, the call should be made to DESI program subsequently made a conscious drug therapy. Health Partners Plans KidzPartners Member Relations at determination of fully effective for most of these will not cover any drugs by companies that do 1-888-888-1212. The call will be evaluated and products and they remain in the marketplace. A not participate in the Federal Rebate Program routed to a pharmacist-on-call. few DESI products remain classified as less or are DESI drugs. Generic drugs must be than fully effective while awaiting final prescribed and dispensed when an A-rated The physician may use the Health Partners administrative disposition. Also classified as generic drug is available. Brand necessary Plans Prior Authorization/Medical Exception DESI are many products listed as identical, prescriptions for drugs with A-rated generics form or a letter of request, but must include the similar, or related to actual DESI products. require prior authorization. following information for quick and appropriate review to take place: Examples of DESI Drugs include: The MAC list sets a ceiling price for the Midrin • Name and recipient number of member reimbursement of certain multisource Vytone • Date of birth of member prescription drugs. This price will typically cover Anusol HC suppositories • Physician’s name, license number, the acquisition of most generics but not Donnatal and specialty branded versions of the same drug. The Tigan • Physician’s phone and fax numbers products selected for inclusion on the MAC list Naldecon are commonly prescribed and dispensed and • Name of primary care physician if different have usually gone through the FDA’s review and approval process. This process assures Prior Authorization (PA) • Drug name, strength, and quantity the following requirements have been met: of medication To ensure that select medications are utilized • Days supply (duration of therapy) and The generic drug will contain the same active appropriately, Prior Authorization may be number of refills ingredient(s)
Recommended publications
  • NG198 Evidence Review E1
    1 2 Research recommendations for review question: For people with mild to 3 moderate acne vulgaris what are the most effective treatment options? 4 Research question - physical modalities 5 What is the effectiveness of physical modalities (such as light devices) in the treatment of 6 acne vulgaris or persistent acne vulgaris-related scarring? 7 Why this is important 8 Physical treatments for acne are popular with people because they have the benefit of 9 treating a local area without systemic effects. They can be used in people with co-morbidities 10 or side effects where other treatments are unsuitable. They are currently available in the 11 private sector but there is no standardisation of treatment modalities or duration. Many 12 different physical therapies have been described for acne including: 13 • Comedone extraction 14 • Phototherapy – including UVB, intense pulsed light, blue and red light 15 • Photochemical therapy (e.g. photodynamic therapy) 16 • Laser 17 • Photopneumatic therapy (e.g. intense pulsed light + vacuum) 18 • Photothermal therapy (eg gold nanoparticles +light or laser) 19 Physical treatments are also used for acne scarring. These include: 20 • Punch excision 21 • CO2 laser 22 • Dermabrasion 23 • Radiofrequency (e.g. fractional microneedling, bipolar) 24 Further research is required to determine the most effective physical treatments for acne and 25 acne scarring. This could open the way to wider availability in the NHS. 26 Table 26: Research recommendation rationale Research question What is the effectiveness of physical modalities (such as light devices) in the treatment of acne vulgaris or persistent acne vulgaris-related scarring? Why is this needed Importance to ‘patients’ or the Physical treatments for acne are popular with people because population they have the benefit of treating a local area without systemic effects.
    [Show full text]
  • Prevention and Management of Intravesical BCG-Related Lower Urinary Tract Symptoms with Prophylactic Pentosan Polysulphate In
    Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms with Prophylactic Pentosan Polysulphate in Patients with Non-Muscle-Invasive Bladder Cancer: A Randomized Controlled Trial Samer Shamout, Simon Tanguay, Maurice Anidjar, Lysanne Campeau CQI Research Grant 2017 INTRODUCTION METHODS / INTERVENTIONS PATIENT IMPACT Study Design • Bacillus Calmette-Guerin (BCG) remains the most effective • Phase 2, double-blind, randomized, placebo-controlled, parallel-group • Improve patient experience by identifying predictor markers prophylactic treatment of intermediate and high-risk non- study rendering patients at higher risk of developing BCG-related muscle invasive bladder cancer. • Multicentre trial involving two partner sites: (Jewish General Hospital, LUTS. McGill University Health Centre) • 30 to 60% of bladder cancer patients experienced systemic • This will guide patient counselling before treatment to inform Outcomes them about associated risks and benefits of the BCG and local adverse events of variable severity following Primary outcomes (change from baseline to end of treatment): treatment. intravesical BCG therapy • Mean change in number of urgency episodes/24hr (3-day bladder diary) • Only 16 to 29% of patients completed all the three-year BCG • Mean change in ICIQ-LUTSqol score • We will determine the role of prophylactic PPS to prevent these treatment regimen. • Mean change in OAB-V8 score LUTS from occurring, particularly if patients are considered at Secondary outcomes (change from baseline to end of treatment): higher risk, and therefore improve patient experience. • Guidelines recommend medications, such as oxybutynin • Mean change in VAS score only phenazopyridine, and propantheline bromide for short term • Mean change in urinary inflammatory markers (TRAIL, IFN, IL-2, IL-10) • The improvement measurements are validated in the symptomatic relief.
    [Show full text]
  • June 2021 Therapeutic Research Center (TRC) Is the Leading Advisory Service on Drug Therapy and Medication Management
    June 2021 Therapeutic Research Center (TRC) is the leading advisory service on drug therapy and medication management. Every month over 400,000 prescribers, pharmacists, and pharmacy technicians rely on our unbiased, evidence-based clinical recommendations to help them improve medication use, prevent medication errors, and improve patient care and outcomes. We also have one of the most extensive CE/CME course offerings in the industry. Our accredited continuing education and continuing medical education courses are trusted and relied on by hundreds of thousands of pharmacists, technicians, and prescribers every month. Therapeutic Research Center does not receive commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. Credit is reported to CPE Monitor, AAFP, and CE Broker as appropriate. Accreditation Information: Therapeutic Research Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians. Pharmacist’s Letter / Therapeutic Research Center is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Therapeutic Research Center / Prescriber’s Letter is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number:080517. Select Therapeutic Research Center courses are also acceptable for American Academy of Family Physicians (AAFP) Prescribed credit, American Osteopathic Association (AOA) credit, and American College of Emergency Physicians (ACEP) Category I Credit. Please refer to the detailed accreditation statements available online for each course. Get started at TherapeuticResearchCenter.com. Log in to access your course list or purchase a course or subscription. For additional assistance, please call 209-472-2240 and we’ll be happy to help you.
    [Show full text]
  • Impact of Tamsulosin, Tolterodine and Drug-Combination On
    African Journal of Urology (2017) 23, 28–32 African Journal of Urology Official journal of the Pan African Urological Surgeon’s Association web page of the journal www.ees.elsevier.com/afju www.sciencedirect.com Original article Impact of Tamsulosin, Tolterodine and drug-combination on the outcomes of lower urinary tract symptoms secondary to post-ureteroscopy ureteral stent: A prospective randomized controlled clinical study a b,∗ a a O. Abdelkader , K. Mohyelden , M.H. Sherif , A.H. Metwaly , b c d a H. Aldaqadossi , A. Shelbaya , H. Khairy , A. Elnashar a Department of Urology, Suez Canal University, Ismailia, Egypt b Department of Urology, Fayoum University, Fayoum, Egypt c Student Hospital, Cairo University, Cairo, Egypt d Department of Urology, Cairo University, Cairo, Egypt Received 17 March 2016; received in revised form 23 June 2016; accepted 23 June 2016 Available online 18 November 2016 KEYWORDS Abstract Anticholinergics; Objectives: To compare the role of alpha-blocker (Tamsulosin) monotherapy, anticholinergic (Tolterodine) ␣-Adrenergic blockers; monotherapy or combination of both drugs versus analgesics in improving post-ureteroscopy (URS) lower Ureter stent; urinary tract symptoms related to double-J ureteral stent. Ureteroscopy Patients and methods: Between January 2009 and June 2013, 160 consecutive patients with ureteric stones were included in this study at 2 tertiary care centers’. Patients were randomized into 4 groups; group A (n = 40) received 0.4 mg Tamsulosin once a day, group B (n = 40) received 4 mg Tolterodine once a day, group C (n = 40) received Tamsulosin 0.4 mg and Tolterodine 4 mg once a day and group D (n = 40) as a control group, received placebo once a day.
    [Show full text]
  • Phenazopyridine | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Phenazopyridine This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US AZO Urinary Pain Relief [OTC]; Baridium [OTC] [DSC]; Pyridium; Urinary Pain Relief [OTC] Brand Names: Canada Phenazo; Pyridium What is this drug used for? It is used to ease pain from a bladder infection. It is used to treat signs of urinary problems. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Kidney disease or liver disease. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Phenazopyridine 1/5 Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists. This drug is not to be used instead of an antibiotic.
    [Show full text]
  • January 2021 Update
    PUBLISHED JULY 08, 2021 OCTOBER/DECEMBER 2020; JANUARY 2021 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES Following is the update to the Highmark Drug Formularies and pharmaceutical management procedures for January 2021. The formularies and pharmaceutical management procedures are updated on a bimonthly basis, and the following changes reflect the decisions made in October, December, and January by our Pharmacy and Therapeutics Committee. These updates are effective on the dates noted throughout this document. Please reference the guide below to navigate this communication: Section I. Highmark Commercial and Healthcare Reform Formularies A. Changes to the Highmark Comprehensive Formulary and the Highmark Comprehensive Healthcare Reform Formulary B. Changes to the Highmark Healthcare Reform Essential Formulary C. Changes to the Highmark Core Formulary D. Changes to the Highmark National Select Formulary E. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Formulary Program 4. Quantity Level Limit (QLL) Programs As an added convenience, you can also search our drug formularies and view utilization management policies on the Provider Resource Center (accessible via NaviNet® or our website). Click the Pharmacy Program/Formularies link from the menu on the left. Highmark Blue Cross Blue Shield Delaware is an independent licensee of the Blue Cross and Blue Shield Association. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides secure, web-based portal between providers and health insurance companies. IMPORTANT DRUG SAFETY UPDATES 03/31/2021 – Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease.
    [Show full text]
  • Acne Vulgaris
    CLINICAL REVIEW What’s New in the Management of Acne Vulgaris Leon H. Kircik, MD A better understanding of acne pathophysiology and the PRACTICE POINTS role of inflammation has, however, yielded a better under- • Sarecycline is the first new antibiotic approved for standing of how existing therapies treat the disease and acne in several years. have led to more comprehensive treatment strategies that • Tazarotene foam 0.1% was relaunched to the market. are multitargeted. Nonetheless, topical and oral antibiotics The foam formulation attempts to impart moisturizing remain mainstays of acne therapy, along with topical reti- effects to offset potential irritation. noids and benzoyl peroxide. Current guidelines of care for • Topical minocycline for acne optimizes the therapeutic acne emphasize strategies that reduce dependence on anti- effects while reducing systemic effects. biotics and minimizecopy the risk for resistance.4 The therapeutic • Clascoterone and cannabidiol currently are under landscape might at last be shifting, with new chemical enti- investigation for acne treatment. ties for acne and several novel formulations in development. Sarecycline: A Novel Tetracycline Tetracyclinenot antibiotics have been used to manage acne Drug development continues to focus on the challenge of treat- since the 1950s, but their method of action in the disease ing acne effectively and safely. Inflammation is a backdrop to has not been fully elucidated.5 In addition to antibiotic the commonly cited elements of the pathophysiology of acne: effects, tetracyclines have been shown to confer anti- Propionibacterium acnes proliferation, increased sebum Dopro- inflammatory properties and other biologic effects.6,7 duction with an increase in circulating androgens, and faulty keratinization.
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • NG198 Evidence Review F1
    FINAL Management options for people with moderate to severe acne vulgaris - network meta-analyses Research recommendations for review question: For people with moderate to severe acne vulgaris what are the most effective treatment options? Research question - reduced dose oral isotretinoin What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Why this is important Oral isotretinoin is prescribed by consultant dermatologist-led team for severe forms of acne resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy. The daily dose typically ranges between 0.5mg to 1mg/kg, however dosage adjustments may be required for people with severe intolerances or whom are at higher risk of developing serious adverse effects. There is limited high-quality data on the efficacy and optimum treatment duration of reduced (less than 0.5mg/kg) daily dose isotretinoin in acne. Furthermore, there have been reports of the successful use of reduced daily dose isotretinoin, including weekly (mini) or bi-weekly (micro) dosage regime as maintenance therapy in people with recurrent relapse despite adequate response to multiple courses of isotretinoin. The evidence for reduced dose isotretinoin as maintenance therapy have been limited to case series and small cohort studies. Further research will help to establish if • reduced daily dose of oral isotretinoin is effective in the treatment of acne vulgaris • reduced dose isotretinoin regime is effective as maintenance therapy; and • the optimum duration of treatment. Table 26: Research recommendation rationale Research question What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Why is this needed Importance to ‘patients’ or the The daily dose of isotretinoin prescribed usually ranges between population 0.5mg – 1mg/kg.
    [Show full text]
  • Drug Formulary
    University of Arkansas March 2017 Use of generic drugs can save both you and your health plan money. This list is not all-inclusive and is not a guarantee of coverage. Plan Benefit design is the final determinate of coverage. Certain drugs (*) may be subject to Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), or Reference Based Pricing (RBP) requirements according to Benefit Design. Unless noted, multisource brand drugs (brand drugs with generic equivalent) are covered at 100% copay. If you have any questions about these requirements or other formulary questions, please contact a MedImpact Healthcare customer service representative at 800-788-2949. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. Drug Type Tier 1 Tier 2 Tier 3 Anti-Infectives Antibiotics – Cephalosporins cefaclor, cefadroxil, cefdinir, CEFTIN susp, SUPRAX 400mg only* (Quantity Limit) cefpodoxime, cefprozil, (QL) cefditoren,cefuroxime, Note: all other Suprax strengths are 100% cephalexin copay Antibiotics - Macrolides azithromycin, clarithromycin, ERY-TAB, ZMAX susp clarithromycin ext-rel, PCE erythromycin delayed-rel, erythromycin ethylsuccinate, erythromycin stearate Antibiotics - Fluoroquinolones ciprofloxacin, ciprofloxacin ext- FACTIVE rel, levofloxacin ,moxifloxacin Antibiotics - Penicillins amoxicillin, amoxicillin- clavulanate, dicloxacillin, penicillin VK Antibiotics – Other* (Prior clindamycin HCl, doxycycline ZYVOX susp*(PA) Authorization) hyclate, linezolid*
    [Show full text]
  • Risk Assessment and Risk Mitigation Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213433Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Division of Risk Management (DRISK) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type NDA Application Number 213433 PDUFA Goal Date August 27, 2020 OSE RCM # 2019-1748 Reviewer Name Yasmeen Abou-Sayed, PharmD Acting Team Leader Jacqueline Sheppard, PharmD Acting Deputy Division Doris Auth, PharmD Director Review Completion Date August 21, 2020 Subject Evaluation of Need for a REMS Established Name clascoterone Trade Name Winlevi Name of Applicant Cassiopea SpA Therapeutic Class Androgen receptor inhibitor Formulation 1% Topical cream Dosing Regimen Applied to the affected areas twice daily 1 Reference ID: 4660260 Table of Contents EXECUTIVE SUMMARY ......................................................................................................................................................... 3 1 Introduction ..................................................................................................................................................................... 3 2 Background ...................................................................................................................................................................... 3 2.1 Product Information ..........................................................................................................................................
    [Show full text]
  • Premium Formulary 1 Quantity Limits — Premium Premium Non-Specialty Quantity Limit
    Your 2021 Premium Standard Formulary Effective July 1, 2021 For the most current list of covered medications or if you have questions: Call the number on your member ID card Visit your plan’s website on your member ID card or log on to the OptumRx app to: • Find a participating retail pharmacy by ZIP code • Look up possible lower-cost medication alternatives • Compare medication pricing and options Understanding your formulary What is a formulary? About this formulary A formulary is a list of prescribed medications or other When differences between this formulary and your pharmacy care products, services or supplies chosen for benefit plan exist, the benefit plan documents rule. This their safety, cost, and effectiveness. Medications are formulary may not be a complete list of medications that listed by categories or classes and are placed into cost are covered by your plan. Please review your benefit plan levels known as tiers. It includes both brand and generic for full details. prescription medications. ® To create the list, OptumRx is guided by the Pharmacy and When does the formulary change? Therapeutics Committee. This group of doctors, nurses, and pharmacists reviews which medications will be covered, how • Medications may move to a lower tier at any time. well the drugs work, and overall value. They also make sure • Medications may move to a higher tier when a generic there are safe and covered options. equal becomes available. • Medications may move to a higher tier or be excluded from How do I use my formulary? coverage on January 1 or July 1 of each year.
    [Show full text]